Fibrogen Inc (NASDAQ:FGEN) had a decrease of 1.63% in short interest. FGEN’s SI was 5.35 million shares in August as released by FINRA. Its down 1.63% from 5.44 million shares previously. With 873,900 avg volume, 6 days are for Fibrogen Inc (NASDAQ:FGEN)’s short sellers to cover FGEN’s short positions. The stock decreased 3.86% or $1.74 during the last trading session, reaching $43.35. About 988,421 shares traded or 44.71% up from the average. FibroGen, Inc. (NASDAQ:FGEN) has declined 23.40% since August 14, 2018 and is downtrending. It has underperformed by 23.40% the S&P500. Some Historical FGEN News: 14/05/2018 – FibroGen Closes Above 200-Day Moving Average: Technicals; 31/05/2018 – ASTELLAS PHARMA INC – FOURTH JAPAN PHASE 3 STUDY FOR ROXADUSTAT MET ITS PRIMARY ENDPOINT; 09/05/2018 – FIBROGEN 1Q LOSS/SHR 50C, EST. LOSS/SHR 51C; 28/03/2018 – Andes Technology Corp. to Present & Exhibit at Design & Reuse IP SOC Conference; 12/04/2018 – $GLPG moving fast into #IPF Ph3 vs. $FGEN still at a snail’s pace; 13/03/2018 Announcing The First Andes Summit – Indigenous Wisdom-Keepers to Gather With People of The North to lnitiate a New Commitment to Earth Healing; 09/05/2018 – FibroGen 1Q Loss/Shr 50c; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom; 07/05/2018 – RESOURCE CAPITAL FUND Vl L.P. ANNOUNCES ACQUISITION OF UNITS IN LOS ANDES COPPER LTD; 31/05/2018 – ASTELLAS & FIBROGEN ANNOUNCE TOPLINE RESULTS FROM DOUBLE-BLIND JAPAN PHASE 3 STUDY FOR ROXADUSTAT IN HEMODIALYSIS CHRONIC KIDNEY DISEASE PATIENTS WITH ANEMIA
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $3.77 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has a 77.55 P/E ratio. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
More notable recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Finance.Yahoo.com which released: “FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet – Yahoo Finance” on August 13, 2019, also Nasdaq.com with their article: “FibroGen (FGEN) Shares Cross Above 200 DMA – Nasdaq” published on August 09, 2019, Globenewswire.com published: “FibroGen Reports Second Quarter 2019 Financial Results Nasdaq:FGEN – GlobeNewswire” on August 08, 2019. More interesting news about FibroGen, Inc. (NASDAQ:FGEN) were released by: Nasdaq.com and their article: “FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates – Nasdaq” published on August 08, 2019 as well as Nasdaq.com‘s news article titled: “Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline – Nasdaq” with publication date: July 30, 2019.
Among 3 analysts covering FibroGen (NASDAQ:FGEN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. FibroGen had 6 analyst reports since February 28, 2019 according to SRatingsIntel. The stock of FibroGen, Inc. (NASDAQ:FGEN) has “Buy” rating given on Thursday, February 28 by Mizuho. The rating was maintained by Jefferies on Thursday, February 28 with “Buy”.
The stock decreased 10.91% or $0.6 during the last trading session, reaching $4.9. About 80,793 shares traded or 7601.91% up from the average. Astea International Inc. (OTCMKTS:ATEA) has 0.00% since August 15, 2018 and is . It has by 0.00% the S&P500.
Astea International Inc. develops, markets, and supports service management software solutions worldwide. The company has market cap of $17.72 million. It offers Astea Alliance, a service management software that addresses the service lifecycle applications, including lead generation, project quotation, service and billing, and asset retirement; and integrates and optimizes business processes for campaigns, call center, depot repair, field service, logistics, projects, and sales and order processing applications. It currently has negative earnings. The firm also provides FieldCentrix Enterprise suite, a service management solution that runs on various mobile devices; and integrates with customer relationship management and ERP applications.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.